Research programme: remyelinating monoclonal antibodies - Acorda Therapeutics/Mayo Clinic

Drug Profile

Research programme: remyelinating monoclonal antibodies - Acorda Therapeutics/Mayo Clinic

Alternative Names: 94.03; M1 monoclonal antibodies; Remyelinating MAbs; Remyelination programme; SCH79.08; SCH94.03; SCH94.32; sHIgM46

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mayo Clinic
  • Developer Acorda Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Myelin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Multiple sclerosis; Spinal cord injuries

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Parenteral)
  • 23 Apr 2013 The lead candidate from this programme, rHIgM22, enters phase I trials for Multiple sclerosis
  • 16 Feb 2012 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top